A Selective Galactose–Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model
(2016) In Journal of Medicinal Chemistry 59(17). p.8141-8147- Abstract
Synthesis of doubly 3-O-coumarylmethyl-substituted thiodigalactosides from bis-3-O-propargyl-thiodigalactoside resulted in highly selective and high affinity galectin-3 inhibitors. Mutant studies, structural analysis, and molecular modeling revealed that the coumaryl substituents stack onto arginine side chains. One inhibitor displayed efficacy in a murine model of bleomycin-induced lung fibrosis similar to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests that blocking galectin-3 glycan recognition is an important antifibrotic drug target.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/05dd2407-2656-40e2-a26f-97b18cbfd652
- author
- Rajput, Vishal K. ; Mackinnon, Alison ; Mandal, Santanu LU ; Collins, Patrick ; Blanchard, Helen ; Leffler, Hakon LU ; Sethi, Tariq ; Schambye, Hans ; Mukhopadhyay, Balaram and Nilsson, Ulf J. LU
- organization
- publishing date
- 2016-09-08
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Medicinal Chemistry
- volume
- 59
- issue
- 17
- pages
- 7 pages
- publisher
- The American Chemical Society (ACS)
- external identifiers
-
- scopus:84986579038
- pmid:27500311
- wos:000383111300032
- ISSN
- 0022-2623
- DOI
- 10.1021/acs.jmedchem.6b00957
- language
- English
- LU publication?
- yes
- id
- 05dd2407-2656-40e2-a26f-97b18cbfd652
- alternative location
- https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00957
- date added to LUP
- 2016-10-03 16:07:42
- date last changed
- 2024-09-06 23:04:14
@article{05dd2407-2656-40e2-a26f-97b18cbfd652, abstract = {{<p>Synthesis of doubly 3-O-coumarylmethyl-substituted thiodigalactosides from bis-3-O-propargyl-thiodigalactoside resulted in highly selective and high affinity galectin-3 inhibitors. Mutant studies, structural analysis, and molecular modeling revealed that the coumaryl substituents stack onto arginine side chains. One inhibitor displayed efficacy in a murine model of bleomycin-induced lung fibrosis similar to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests that blocking galectin-3 glycan recognition is an important antifibrotic drug target.</p>}}, author = {{Rajput, Vishal K. and Mackinnon, Alison and Mandal, Santanu and Collins, Patrick and Blanchard, Helen and Leffler, Hakon and Sethi, Tariq and Schambye, Hans and Mukhopadhyay, Balaram and Nilsson, Ulf J.}}, issn = {{0022-2623}}, language = {{eng}}, month = {{09}}, number = {{17}}, pages = {{8141--8147}}, publisher = {{The American Chemical Society (ACS)}}, series = {{Journal of Medicinal Chemistry}}, title = {{A Selective Galactose–Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model}}, url = {{http://dx.doi.org/10.1021/acs.jmedchem.6b00957}}, doi = {{10.1021/acs.jmedchem.6b00957}}, volume = {{59}}, year = {{2016}}, }